文献速递银屑病与炎症性皮肤病

古塞奇尤单抗与乌司奴单抗治疗中重度斑块状银屑病的调整间接比较:COMPASS分析

Adjusted treatment COMPArisons between guSelkumab and uStekinumab for treatment of moderate-to-severe plaque psoriasis: the COMPASS analysis.
PubMed 文献 · Br J Dermatol · 2020-01-29

本研究基于VOYAGE 1/2试验中古塞奇尤单抗和NAVIGATE试验中乌司奴单抗的个体患者数据,采用多变量logistic回归调整临床相关协变量,比较两种药物维持治疗中重度斑块状银屑病的相对疗效。结果显示,古塞奇尤单抗在第16周和第40周达到PASI 90、PASI 75和PASI 100缓解的概率均显著高于乌司奴单抗。

要点

  • 古塞奇尤单抗在第16周和第40周达到PASI 75和PASI 100的概率也显著更高。

核心结论

  • 调整分析显示,古塞奇尤单抗在第40周内达到并维持PASI缓解的概率显著高于乌司奴单抗。

研究设计与样本

  • 基于随机对照试验个体患者数据的调整间接比较,汇总VOYAGE 1和2试验中古塞奇尤单抗数据,与NAVIGATE试验中乌司奴单抗数据比较。

主要发现

  • 古塞奇尤单抗在第16周和第40周达到PASI 75和PASI 100缓解的概率也显著高于乌司奴单抗。

关键数值与推荐

  • 比较古塞奇尤单抗100 mg与乌司奴单抗45 mg或90 mg,评估至第40周PASI 90、75和100应答的达到与维持。
  • 采用多变量logistic回归模型调整年龄、性别、银屑病病程等临床相关协变量。
  • 疗效以比值比(OR)和预测缓解概率表示。

临床怎么用

  • 对于乌司奴单抗初治的中重度斑块状银屑病患者,古塞奇尤单抗在维持PASI应答方面可能提供更高概率。

局限性

  • 研究为基于随机对照试验个体患者数据的调整间接比较,非头对头直接比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Guselkumab is an interleukin-23 inhibitor indicated for the treatment of moderate-to-severe plaque psoriasis in adults. Guselkumab has demonstrated additional benefit in patients with early inadequate response to ustekinumab. Long-term efficacy comparisons of guselkumab and ustekinumab are currently lacking among ustekinumab-naive patients. OBJECTIVES: To assess the relative efficacy of guselkumab and ustekinumab for maintenance therapy of moderate-to-severe plaque psoriasis, using individual patient data (IPD) from randomized controlled trials. METHODS: IPD for guselkumab from the VOYAGE 1 and 2 trials were pooled and compared with IPD for ustekinumab from the NAVIGATE trial. Multivariable logistic regression analyses compared guselkumab 100 mg and ustekinumab 45 mg or 90 mg for the achievement and maintenance of Psoriasis Area and Severity Index (PASI) 90, 75 and 100 responses up to 40 weeks. The regression models accounted for a range of clinically relevant covariates (e.g. age, sex, psoriasis duration). Relative efficacy was expressed using odds ratios (ORs) and predicted probability of treatment response associated with each intervention. RESULTS: Patients receiving guselkumab had significantly higher probabilities of achieving a PASI 90 response than patients receiving ustekinumab, at both week 16 [70·4% vs. 46·0%, OR 2·79, 95% confidence interval (CI) 2·22-3·45] and week 40 (74·2% vs. 54·5%, OR 2·40, 95% CI 1·89-3·13]. Guselkumab was also associated with a significantly increased likelihood of achieving both PASI 75 and PASI 100 responses at weeks 16 and 40, compared with ustekinumab. CONCLUSIONS: Adjusted analyses leveraging IPD demonstrate that guselkumab has a significantly higher probability of achieving and maintaining PASI treatment responses through week 40 than ustekinumab does.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Diels J, Thilakarathne P, Cameron C, et al. Adjusted treatment COMPArisons between guSelkumab and uStekinumab for treatment of moderate-to-severe plaque psoriasis: the COMPASS analysis. Br J Dermatol. 2020. PMID: 31652347. doi:10.1111/bjd.18634

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。